- Effective communication with target patients/families/care professionals and RETAINING them
- How inclusion of AI looks like in this communication, trust building, meeting needs and retaining engagement, from:
- Care researchers’ perspective
- Care Professionals’ perspective, and most importantly,
- Caregivers’ perspective (lived experience and real-world-evidence) in the context of “rare diseases”
Archives: Agenda
Registration and refreshments
Cold Is Easy. Control Is Not. How smart logistics improve PCM benefits in pharmaceutical shipments
- PCMs provide predictable thermal buffering
- When and why temperature control fails in pharma logistics
- Dry ice is powerful – but not trivial
- How to overcome these failures best – (where) can AI help?
- Logistics tools improving PCM benefits
Navigating the future of clinical trial logistics
Insights from the DHL logistics trend radar
- Key logistics trends impacting life sciences & healthcare
- Customer insights on adoption and priorities: LTR ECHO
- What’s next in the DHL logistics trend radar
CLOSING PANEL DISCUSSION: How AI is powering a new era of cancer drug discovery and development
- Moving from basic functionalities to more meaningful impact and examples of this in practice
- When AI is progressing so quickly, how will regulation evolve to match this speed?
- When is AI not the answer?
- How AI has revolutionised innovative ways of collecting data, biosimulation, and early disease diagnosis for oncology trials
Moderator: Asiyah Nawab, Senior Healthcare Analyst (Immunology Team), GlobalData
THIS SESSION WILL BE IN THE ONCOLOGY CONFERENCE ROOM
Afternoon refreshments, networking and prize draw
Clinical trials in rare immunology disorders
- Overview of rare diseases in Immunology
- Pharma focus on rare diseases in Immunology for drug development – where do industry interests lie?
- Challenges in rare disease trials in immunology
- Case Study – Sarepta’s Elevidys in Duchenne Muscular Dystrophy (DMD)
The role of patient research NGOs in drug development – illustrated by the Children’s Tumor Foundation’s leadership role in the EU PEARL project
- Patient driven infrastructure – NF patient registry, NF Preclinical Hub, NF Clinic Network, NF Data Portal – to accelerate trials and insights
- CTF served as IMI research partner on EU PEARL NF1; CTF Europe launched to expand platform trials
- EU PEARL NF1: adaptive platform basket across PN, cNF, LGG/OPG; observational entry → randomization; add/drop arms, early go/ no go signals
- Addresses EMA orphan challenges via clear estimands and central oversight; efficient, de risked paediatric evidence
- NGO impact: contributed to first NF approvals; 60+ US trials; now scaling European execution
End of conference
Technology Spotlight: The digital revolution in clinical trials: relabelling with digital display labels
- The landscape of clinical trials is undergoing a transformative shift as digital technologies continue to permeate every aspect of the healthcare industry
- One potential transformation could be the replacement of traditional paper-based relabelling in clinical trials with digital display labels
- The integration of digital display labels into clinical trials represents a significant leap forward in the industry. As this technology matures and becomes more widely adopted, it could impact the way clinical trials are conducted and managed especially in the areas of remote monitoring, adaptive trials, and patient engagement
- In this session, we will explore the challenges associated with traditional relabelling processes in clinical trials, the advantages of adopting digital display labels, and the potential impact on the future of healthcare research